LLY - Eli Lilly announces U.S. availability of weight loss drug Zepbound

2023-12-05 07:58:20 ET

Eli Lilly ( NYSE: LLY ) announced on Tuesday the U.S. availability of its weight loss drug Zepbound (tirzepatide), a GIP/GLP-1 duo agonist.

Last month, the U.S. Food and Drug Administration approved the Zepbound for chronic weight management, after adults taking the injection lost on average 48 lb. at the highest dose in a clinical trial.

The medicine is indicated for adults with obesity (with a BMI of 30 kg/m2 or greater), or those who are overweight (with a BMI of 27 kg/m2 or greater) and also have weight-related medical problems. It is available in six doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg) through a prescription that can be filled at retail and mail-order pharmacies.

Patients who are commercially insured with coverage for Zepbound may be eligible to pay $25 for a 1-month or 3-month prescription. Ones who are commercially insured without Zepbound coverage will have to pay $550 for a 1-month prescription.

The list price of Zepbound has been set at $1,059.87 for all six doses.

More on Eli Lilly

• Bubble Warning: Unrealistic Growth Priced In And Multiple Risk Factors For Eli Lilly
• Eli Lilly and Company (LLY) Presents at 6th Evercore ISI HealthCONx Conference (Transcript)
• Eli Lilly: Perfectly Priced Healthcare Giant
• Eli Lilly further extends tender offer to buy Point Biopharma
• FDA grants second accelerated approval to Lilly's Jaypirca

For further details see: